Palomar/Gillette deal enters phase two:
This article was originally published in Clinica
Palomar Medical Technologies and Gillette have embarked on the second phase of a joint effort to develop and commercialise a patented home-use, light-based hair removal device for women. Palomar, of Burlington, Massachusetts, will disclose further information on proprietary optical hair-removal technology to assist in the research and Boston-based Gillette, following an amendment to the original agreement, will provide an additional $2.1m in development funding. The financing will be spread over a nine-month extension of the development phase, which is expected to be completed by August 31 2006.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.